AstraZeneca PLC Steps Up Push Into Cancer Immunotherapy, Falls Behind Rivals Such As Bristol-Myers Squibb Company, Merck & Co., Inc., And Roche

(Reuters) - AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types.

The company is seen as No. 4 in a race to develop the first drug in a new class that fights cancer by unleashing the body's immune system, behind rivals Roche, Merck & Co and Bristol-Myers Squibb.

But its MEDI4736 medicine is still viewed as a highly promising agent, both on its own and in combination with other treatments.

Help employers find you! Check out all the jobs and post your resume.